These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18383071)

  • 1. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?
    Jankovic J
    Ann Neurol; 2008 Mar; 63(3):267-9. PubMed ID: 18383071
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
    Xu K; Bastia E; Schwarzschild M
    Pharmacol Ther; 2005 Mar; 105(3):267-310. PubMed ID: 15737407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of caffeine on the freezing of gait in Parkinson's disease.
    Kitagawa M; Houzen H; Tashiro K
    Mov Disord; 2007 Apr; 22(5):710-2. PubMed ID: 17373724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease.
    Factor S; Mark MH; Watts R; Struck L; Mori A; Ballerini R; Sussman NM;
    Parkinsonism Relat Disord; 2010 Jul; 16(6):423-6. PubMed ID: 20338800
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Caffeine and Chocolate as New Options in the Treatment of Parkinson's Disease?].
    Köglsperger T; Dieterich M
    Fortschr Neurol Psychiatr; 2023 Jun; 91(6):239-240. PubMed ID: 37336208
    [No Abstract]   [Full Text] [Related]  

  • 10. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
    Reichmann H
    Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply: a randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease.
    Schenkman M
    Mov Disord; 2010 Mar; 25(4):524. PubMed ID: 20077472
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease.
    Kitta T; Yabe I; Takahashi I; Matsushima M; Sasaki H; Shinohara N
    Int J Urol; 2016 Oct; 23(10):893-894. PubMed ID: 27388933
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial counseling in Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S160-2. PubMed ID: 12211156
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with istradefylline for postural abnormalities in Parkinson's disease.
    Deutschländer AB
    Neurol Neurochir Pol; 2019; 53(4):239-241. PubMed ID: 31469906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cappuccino a day ... caffeine may ward off Parkinson's disease.
    Sobel RK
    US News World Rep; 2000 Jun; 128(22):63. PubMed ID: 10977215
    [No Abstract]   [Full Text] [Related]  

  • 19. Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?
    Feigin A
    Neurology; 2003 Aug; 61(3):286-7. PubMed ID: 12913183
    [No Abstract]   [Full Text] [Related]  

  • 20. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.
    Knebel W; Rao N; Uchimura T; Mori A; Fisher J; Gastonguay MR; Chaikin P
    J Clin Pharmacol; 2012 Oct; 52(10):1468-81. PubMed ID: 22162533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.